Login to Your Account



Sharpens Orthopedic Focus

BioMimetic Scoring Again: $40M For Dental Business

By Randall Osborne


Tuesday, December 18, 2007
Having proven the efficacy of its bone-graft product for the foot and ankle in a Canadian pivotal trial, BioMimetic Therapeutics Inc. is selling rights for the marketed periodontal therapy based on the same platform, thereby gaining $40 million in cash that will be used for other product development. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription